FLT1 Protein (AA 27-687, C-Term)

Catalog No. ABIN2666538

Recombinant FLT1 protein expressed in HEK-293 Cells.

Quick Overview for FLT1 Protein (AA 27-687, C-Term) (ABIN2666538)

Target: FLT1 (Fms-Related tyrosine Kinase 1 (VEGFR1) (FLT1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 27-687, C-Term

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 20 - 100 ng/ml, corresponding to a specific activity of 1 - 5 x 104 units/mg, as determined by inhibition of HUVEC cell proliferation.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 20 mM MOPS, 150 mM NaCl, 1 mM CHAPS pH 6.5.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: FLT1 (Fms-Related tyrosine Kinase 1 (VEGFR1) (FLT1))

Alternative Name: VEGFR1

Background: The VEGF family includes five members, VEGFA (VEGFA165), VEGFB, VEGFC, VEGFD and placenta growth factor (PLGF). Structurally, these growth factors are homodimers although heterodimers have been described that are composed of VEGFA and PLGF. There are three VEGF receptor tyrosine kinases: VEGFR1 (Flt1), VEGFR2 (Flk1), and VEGFR3 (Flt4). The expression of these receptors is overlapping, nevertheless, a distribution pattern has been reported: VEGFR1 is expressed on monocytes and macrophages, VEGFR2 on vascular endothelial cells, and VEGFR3 on lymphatic endothelial cells. VEGFR1 and VEGFR2 share 43.2 % amino acid sequence homology and are structurally similar. VEGFR1 is an angiogenic and anti-angiogenic factor depending on the ligand binding it (PLGF-1 inhibits angiogenesis, whereas VEGF and PLGF2 are pro-angiogenic). Also, VEGFR1 mediates the angiostatic effect of pigment epithelium-derived factor (PEDF). A soluble form of VEGFR1 was initially identified in conditioned culture medium of HUVEC cells and it was found that it binds with high affinity to VEGFA. Soluble VEGFR1 and VEGFR2 act as decoy receptors for VEGFA, regulating the availability of VEGFA of which there are at least four different alternatively spliced soluble proteins. sVEGFR1 expression is upregulated by hypoxic conditions via HIF1-α in cytotrophoblasts. In preeclampsia activated platelets bind to monocytes to produce sVEGFR1. Increased circulating sVEGFR1 has been correlated with reduced free PLGF and reduced free VEGF in the blood compared to normal pregnancies. In addition, sVEGFR1 has been detected in cornea, and it is essential for preserving the avascular ambit of the cornea.

Molecular Weight: The 674 amino acid recombinant protein has a predicted molecular mass of approximately 76.2 kDa. The DTT-reduced and non-reduced protein migrate at approximately 120 kDa by SDS-PAGE. The predicted N-terminal amino acid is Ser.

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGFR1 Specific Signals